Edition:
United Kingdom

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Capital Market

0.50USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$0.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
259,981
52-wk High
$5.72
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Flex Pharma Inc Files For Mixed Shelf Of Up To $100 Mln
Wednesday, 24 Apr 2019 

April 24 (Reuters) - Flex Pharma Inc ::FLEX PHARMA INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING.  Full Article

Flex Pharma And Salarius Pharmaceuticals Announce Merger Agreement
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Flex Pharma Inc ::FLEX PHARMA AND SALARIUS PHARMACEUTICALS ANNOUNCE MERGER AGREEMENT TO ACCELERATE CLINICAL DEVELOPMENT OF NOVEL EPIGENETIC THERAPY FOR CANCER.FLEX PHARMA INC - UPON CLOSING OF TRANSACTION, FLEX PHARMA IS EXPECTED TO BE RENAMED SALARIUS PHARMACEUTICALS, INC..FLEX PHARMA INC - FLEX PHARMA STOCKHOLDERS WILL OWN APPROXIMATELY 19.9% OF COMBINED COMPANY.FLEX PHARMA INC - LEADERSHIP OF SALARIUS' CURRENT MANAGEMENT TEAM TO BE LED BY CHIEF EXECUTIVE OFFICER, DAVID ARTHUR.FLEX PHARMA INC - CURRENT SALARIUS INVESTORS WILL OWN APPROXIMATELY 80.1% OF COMBINED COMPANY.FLEX PHARMA INC - CO'S CEO, WILLIAM MCVICAR IS EXPECTED TO JOIN BOARD OF DIRECTORS OF COMBINED COMPANY FOLLOWING CLOSING OF TRANSACTION.FLEX PHARMA INC - TRANSACTION HAS BEEN APPROVED UNANIMOUSLY BY BOARD OF DIRECTOR OF FLEX PHARMA AND BOARD OF MANAGERS OF SALARIUS.FLEX PHARMA - SALARIUS' RECENTLY COMPLETED $6.4 MILLION PRIVATE PLACEMENT AND CASH FROM FLEX PHARMA EXPECTED TO FUND COMBINED COMPANY TO MID-2020.  Full Article

Flex Pharma Q3 Loss Per Share $0.15
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Flex Pharma Inc ::FLEX PHARMA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.15.Q3 REVENUE $251,000.  Full Article

Flex Pharma Estimates Up To ~$2.3 Mln In Restructuring Costs Plus Prior Disclosed Costs
Wednesday, 20 Jun 2018 

June 20 (Reuters) - Flex Pharma Inc ::FLEX PHARMA-ESTIMATES WILL INCUR COSTS UP TO ABOUT $2.3 MILLION RELATED TO RESTRUCTURING IN ADDITION TO PRIOR DISCLOSED ONE-TIME TERMINATION BENEFIT COSTS.  Full Article

Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Flex Pharma Inc ::FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​.  Full Article

Flex Pharma Q3 loss per share $0.54
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc ::Flex Pharma reports third quarter 2017 financial results.Q3 loss per share $0.54.Q3 revenue $414,000 versus I/B/E/S view $477,000.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - ‍expects to have sufficient capital to fund operations into early 2019​.  Full Article

Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc :Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS.Flex Pharma - ‍data from exploratory phase 2 trial of FLX-787 showed statistically significant reduction in cramp-associated pain intensity & stiffness​.Flex Pharma Inc - ‍FLX-787 was generally well tolerated​.  Full Article

Flex Pharma initiates CMT phase 2 trial with FLX-787 in US
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Flex Pharma Inc :Flex Pharma initiates CMT phase 2 trial with FLX-787 in US.Flex Pharma Inc - ‍ALS phase 2 trial currently underway​.Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​.  Full Article

Flex Pharma Q2 loss per share $0.51
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Flex Pharma Inc :Flex Pharma reports second quarter 2017 financial results.Q2 loss per share $0.51.Q2 revenue $336,000.Q2 revenue view $515,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - expects to have "sufficient" capital to fund its operations into early 2019.  Full Article

Flex Pharma initiates ALS phase 2 trial with flx-787 in U.S.
Tuesday, 1 Aug 2017 

Aug 1 (Reuters) - Flex Pharma Inc :Flex Pharma initiates ALS phase 2 trial with flx-787 in us.Says expects to report topline results from this study in middle of 2018.Says also intends to initiate a phase 2 clinical trial in cmt this quarter.  Full Article

No consensus analysis data available.